Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.67 USD
-0.25 (-13.02%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.66 -0.01 (-0.60%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
PACB 1.67 -0.25(-13.02%)
Will PACB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PACB
IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates
Pacific Biosciences of California (PACB) Flat As Market Sinks: What You Should Know
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacific Biosciences of California (PACB) Ascends While Market Falls: Some Facts to Note
PacBio's (PACB) Revio System to Boost Novogene's German Lab
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
Other News for PACB
What You Missed On Wall Street This Morning
Novogene to Power Cancer, Rare Disease, and Environmental Research with PacBio Sequencing
PacBio announces Novogene is using its Revio
What You Missed On Wall Street On Tuesday
Dow Rallies To All-Time Highs, Small Caps Outperform Tech, Gold Hits Records On Heightened September Rate Cut Bets: What's Driving Markets Tuesday?